SEATTLE–(BUSINESS WIRE)– #Biotechnology–Compvide announced a strategic collaboration with OpZira to support growth and accelerate development of the CIMED™ platform.
Author: Business Wire
EZContacts Takes On Overpriced Luxury Eyewear With Vesari, Its First In-House Brand
RIDGEFIELD PARK, N.J.–(BUSINESS WIRE)–EZContacts takes on luxury eyewear markups with Vesari. Runway-inspired frames at one honest price: $95, prescription lenses included.
Dompé somministra la dose al primo paziente nello studio di fase 3 su cenegermin-bkbj per la NAION
MILANO & SAN MATEO, Calif.–(BUSINESS WIRE)–Dompé, azienda biofarmaceutica con attività in Italia e negli Stati Uniti, ha annunciato l’arruolamento del primo paziente in uno studio di fase 3 su cenegermin-bkbj per il trattamento della neuropatia ottic…
Dompé Doses First Patient in Phase 3 Study of Cenegermin-bkbj in NAION
MILAN & SAN MATEO, Calif.–(BUSINESS WIRE)–Dompé advances cenegermin-bkbj into Phase 3 for NAION, a rapid vision-loss condition with no FDA-approved treatment options.
Dompé verabreicht erste Dosis in Phase-3-Studie zu Cenegermin-bkbj bei NAION
MAILAND & SAN MATEO, Calif.–(BUSINESS WIRE)–Dompé, ein biopharmazeutisches Unternehmen mit Niederlassungen in Italien und den USA, gab heute bekannt, dass der erste Patient in eine Phase-3-Studie zu Cenegermin-bkbj für die Behandlung der nicht-arteri…
Dompé administre la première dose à un patient dans le cadre de l’étude de phase 3 sur le cenegermin-bkbj dans le traitement de la NAION
MILAN & SAN MATEO, Calif.–(BUSINESS WIRE)–Dompé, une société biopharmaceutique présente en Italie et aux États-Unis, a annoncé que le premier patient avait été recruté dans une étude de phase 3 sur le cenegermin-bkbj pour le traitement de la neuropat…
Dompé administra la dosis al primer paciente en el estudio de fase 3 de cenegermin-bkbj para NOIANA
MILÁN & SAN MATEO, Calif.–(BUSINESS WIRE)–Dompé, una compañía biofarmacéutica con operaciones en Italia y los Estados Unidos, anunció la inscripción del primer paciente en un estudio de fase 3 de cenegermin-bkbj para el tratamiento de la neuropatía ó…
Dompé dient de eerste patiënt een dosis toe in het fase 3-onderzoek naar Cenegermin-bkbj voor NAION
MILAAN & SAN MATEO, Calif.–(BUSINESS WIRE)–Dompé, een toonaangevend biofarmaceutisch bedrijf met activiteiten in Italië en de VS, maakt bekend dat de eerste patiënt is ingeschreven voor een fase 3-onderzoek naar cenegermin-bkbj voor de behandeling va…
Tenpoint Therapeutics Announces United Kingdom Submission of Marketing Authorization Application to the Medicines and Healthcare Products Regulatory Agency (MHRA) for the Treatment of Blurry Close-Up Vision (Presbyopia) in Adults
LONDON & WARREN, N.J.–(BUSINESS WIRE)–Tenpoint Therapeutics announced the submission of an MAA to the United Kingdom’s MHRA for the review of YUVEZZI™ for the treatment of presbyopia.
Tenpoint Therapeutics Announces United Kingdom YUVEZZI™ Submission of Marketing Authorization Application to the Medicines and Healthcare Products Regulatory Agency (MHRA) for the Treatment of Blurry Close-Up Vision (Presbyopia) in Adults
LONDON & WARREN, N.J.–(BUSINESS WIRE)–Tenpoint Therapeutics, Ltd., a global commercial ophthalmic pharmaceutical company focused on developing groundbreaking treatments to improve vision in the aging eye, today announced the submission of a Marketing…
Sydnexis Announces FDA Advisory Committee Meeting to Review NDA for SYD-101 for Pediatric Progressive Myopia
DEL MAR, Calif.–(BUSINESS WIRE)–Sydnexis Announces FDA Advisory Committee Meeting to Review NDA for SYD-101 for Pediatric Progressive Myopia
Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off the shelf”, cell therapies for serious medic…
Physicians Across Retina Consultants of America Network to Present Key Trial Data and Clinical Insights at ASRS 2026
SOUTHLAKE, Texas–(BUSINESS WIRE)–Retina specialists across the Retina Consultants of America (RCA) network will present clinical trial data, real-world evidence, surgical techniques, and novel treatment approaches across more than 30 sessions at the …
Ollin Biosciences Announces Upcoming Presentations of OLN324 Data in Diabetic Macular Edema and Wet Age-Related Macular Degeneration at the American Society of Retina Specialists (ASRS) 44th Annual Scientific Meeting
AUSTIN, Texas–(BUSINESS WIRE)–Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced upcoming oral presentations featuring results from its randomized, head-to-he…
Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced topline results from its Phase 2 study evaluating BL1107 in patien…
AM Best Withdraws Credit Ratings of Vision Service Plan and Its Subsidiaries
OLDWICK, N.J.–(BUSINESS WIRE)–AM Best has affirmed the Financial Strength Rating (FSR) of A- (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of “a-” (Excellent) of Vision Service Plan (Rancho Cordova, CA) and its subsidiaries, col…
Biocon Announces Publication of Pivotal Clinical Data Supporting Effectiveness of Yesafili™, a Biosimilar to Eylea® (Aflibercept)
BENGALURU, India & BRIDGEWATER, N.J.–(BUSINESS WIRE)– #Biosimilars–Biocon Limited (BSE: 532523; NSE: BIOCON), an innovation‑led global biopharmaceutical company, today announced the publication of two important clinical studies supporting the effect…
Bausch + Lomb Introduces Orphia™, an AI-Powered Digital Health Platform Built to Return Physicians to Patient Care
VAUGHAN, Ontario, & MENLO PARK, Calif.–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the creation of Orphia™, a new AI-powered di…
iHealthScreen Receives U.S. FDA 510(k) Clearance (K253704) for iPredict-DR, an AI-Powered Software for Automated Diabetic Retinopathy Screening
RICHMOND HILL, N.Y.–(BUSINESS WIRE)– #AI–iHealthScreen, Inc., a healthcare AI company developing Software as a Medical Device (SaMD) for retinal and cardiovascular disease screening and preventive healthcare, today announced FDA 510(k) clearance (K2…
GenSight Biologics Reports Cash Position as of June 30, 2026, and Provides Business Updates
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…